Back to Search
MARK MCCLUNG, MD
MD
Psychiatry Physician
NPI: 1861501645Individual
Specialties, Licenses & Credentials
Psychiatry PhysicianPrimary
Psychiatry & Neurology — Psychiatry
Code: 2084P0800X
MD00032789(WA)
Research & Publications (20)
The clinical and epidemiologic consequences of redefining treatment criteria: who should be treated?
PMID 19287893·Salud Publica Mex·2009
6-review
Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
PMID 18950736·Bone·2009
2-rct
Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
PMID 19671655·N Engl J Med·2009
4-observational
Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.
PMID 18226668·Contraception·2008
1-meta
European guidance for osteoporosis: an American perspective.
PMID 18846979·Pol Arch Med Wewn·2008
8-other
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.
PMID 18087660·Osteoporos Int·2008
3-trial
Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis.
PMID 17938984·Osteoporos Int·2008
4-observational
Fracture risk remains reduced one year after discontinuation of risedronate.
PMID 17938986·Osteoporos Int·2008
2-rct
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.
PMID 18539106·Bone·2008
3-trial
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
PMID 17920005·Bone·2008
2-rct
Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
PMID 17968610·Osteoporos Int·2008
8-other
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
PMID 17708711·J Bone Miner Res·2007
3-trial
Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
PMID 17726081·J Clin Endocrinol Metab·2007
4-observational
"Because I know it will!": placebo effects of an ergogenic aid on athletic performance.
PMID 17876973·J Sport Exerc Psychol·2007
8-other
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
PMID 17468062·Bone·2007
4-observational
Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation.
PMID 16860045·Contraception·2006
2-rct
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2025 1ST AVE STE 760
SEATTLE, WA 98121 - Phone
- (206) 728-5878
Quick Facts
- NPI
- 1861501645
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile